KM Research Hub
← 返回论文库
部分完成 入排:符合 图源:可得 入排置信度 0.98

Population pharmacokinetics and exposure-response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study.

Xiaoying Zhao, Junjie Ding, Jiajia Zhao, Ling Zhang, Aburough Abegesah, Yu-Qian Zhang, Cathy O'Brien, Gary J Doherty, Allen C Chen, KyoungSoo Lim, Song Ren, Peiming Ma, Diansong Zhou

Br J Clin Pharmacol 92(3) 980-996

PMID41222125
PMCIDPMC12930014
DOI10.1002/bcp.70287
发表日期2025-11-12
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

AIMS: In the AEGEAN study, perioperative durvalumab plus platinum-based neoadjuvant chemotherapy for patients with resectable stage II to IIIB (N2) non-small-cell lung cancer (NSCLC) demonstrated a favourable benefit-risk profile. This study evaluated population pharmacokinetics (PopPK) and exposure-response (ER) relationships of durvalumab in patients with resectable NSCLC. METHODS: The durvalumab PopPK model was updated by integrating PK data from the AEGEAN study. Individual exposure metrics were derived from empirical Bayes estimates for ER analyses relating to safety (adverse events [AEs]) and efficacy (pathological complete response [pCR] and event-free survival [EFS]). RESULTS: A two-compartment model with a time-dependent clearance adequately characterized durvalumab PK data. The typical parameter estimates clearance, central and peripheral volume of distribution were 0.285 L/day (relative standard error: 1.68%), 3.42 L (0.962%) and 2.30 L (2.09%), respectively. All identified covariates caused ≤21% of change on durvalumab PK parameters, indicating no meaningful impact on durvalumab exposure. At the plateaued dose level of durvalumab 1500 mg, a flat relationship was observed between durvalumab PK exposure and EFS, confirmed by Cox proportional hazards analysis, and pCR, confirmed by logistic regression analysis. Logistic regression analysis indicated that no clinically relevant relationships were observed between durvalumab PK exposure and safety endpoints, including grade ≥3 treatment-related AEs, grade ≥3 treatment-related AEs of special interest, and AEs leading to treatment discontinuation. CONCLUSIONS: These results support the novel perioperative durvalumab regimen for patients with resectable NSCLC from the AEGEAN study, and no dose adjustment is necessary based on the PopPK and ER analyses.

KM 提取结果

1 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure6 个面板

FIGURE 3

FIGURE 3 EFS Kaplan–Meier plots for durvalumab exposure metrics by quartiles at dose 1 (A) and steady state (B). Abbreviations: AUC, area under the serum concentration–time curve; AUC, dose 1, AUC from time 0 to the end of dosing interval following the first dose; AUC ss , AUC at steady state; C max , maximum concentration; C max , dose 1, C max following the first dose; C max ,ss, C max at steady state; C min , trough concentration; C min , dose 1, C min following the first dosing cycle; C min ,ss, C min at steady state; CI, confidence interval; EFS, event‐free survival; QX, quartile X.

AUC_dose_1_quartiles

EFS

FIGURE 3 · Panel AUC_dose_1_quartiles

complete 待 EXE 对齐 预期 5 条 已提取 5 条

Panel AUC_dose_1_quartiles 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Cmax_dose_1_quartiles

EFS

FIGURE 3 · Panel Cmax_dose_1_quartiles

quality_warning 待 EXE 对齐 预期 5 条 已提取 4 条

Panel Cmax_dose_1_quartiles 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线交叉次数异常,需检查跨图跳线或误跟踪曲线缺失:预期 5 条,实际恢复 4 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
Cmin_dose_1_quartiles

EFS

FIGURE 3 · Panel Cmin_dose_1_quartiles

failed 待 EXE 对齐 预期 5 条 已提取 0 条

Panel Cmin_dose_1_quartiles 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 5 条,实际恢复 0 条曲线 1:off origin start曲线 1:extreme upward reversal曲线 2:off origin start
No curves extracted
查看结果
AUC_steady_state_quartiles

EFS

FIGURE 3 · Panel AUC_steady_state_quartiles

complete 待 EXE 对齐 预期 5 条 已提取 5 条

Panel AUC_steady_state_quartiles 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线交叉次数异常,需检查跨图跳线或误跟踪曲线交叉次数异常,需检查跨图跳线或误跟踪曲线 2:flat topline artifact曲线 5:extreme jump
查看结果
Cmax_steady_state_quartiles

EFS

FIGURE 3 · Panel Cmax_steady_state_quartiles

quality_warning 待 EXE 对齐 预期 5 条 已提取 4 条

Panel Cmax_steady_state_quartiles 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 5 条,实际恢复 4 条曲线 1:short span曲线 4:extreme jump曲线 4:off origin start
查看结果
Cmin_steady_state_quartiles

EFS

FIGURE 3 · Panel Cmin_steady_state_quartiles

quality_warning 待 EXE 对齐 预期 5 条 已提取 2 条

Panel Cmin_steady_state_quartiles 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 5 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Diagnostic plots. (A) Basic goodness of fit plots (all studies). Blue line = trend line through the data points, the blue area is the 95% confidence interval around it. Abbreviations: CWRES, conditional weighted residuals; pcVPC, prediction corrected visual predictive check. (B) pcVPC of the final model vs. time after last dose in AEGEAN. Solid and dashed lines = the median, 5th, and 95th percentiles of the observations. Shaded red and blue areas = the 95% confidence interval of the median, 5th and 95th percentiles predicted by the model. Abbreviations: pcVPC, prediction‐corrected visual predictive check. (C) Impact of covariates on durvalumab clearance and central volume at steady state – tornado plot. Dashed area = the percentage change of model parameter for the 5th and 95th percentile of the relevant covariates relative to the median parameter estimates (for continuous covariates), or relative to the most frequent category (for categorical covariates). Abbreviations: BW, bodyweight; Chemo, chemotherapy; CRCL, creatinine clearance; Durva, durvalumab; ECOG, Eastern Cooperative Oncology Group; NSCLC, non‐small‐cell lung cancer; Treme, tremelimumab.
非 KM Figure
FIGURE 2FIGURE 2 Durvalumab exposure by non‐Chinese and Chinese patients (AEGEAN study). Blue dots = the simulated PK exposure parameter based on PopPK model. Black solid lines = the median of the observations, the lower and upper parts of the boxplot are 25% and 75% of the distribution. Lower and upper lines = the median −1.5 IQR and median + 1.5 IQR, respectively. P ‐value calculated from t ‐test. Abbreviations: AUC, area under the serum concentration–time curve; PK, pharmacokinetic; PopPK, population pharmacokinetics.
非 KM Figure
FIGURE 4FIGURE 4 Distribution of AUCdose 1 (AUC1d) after first dose of durvalumab in patients with (yes) and without (no) pCR (A) /specified AEs (B). Black hollow circles = values observed in non‐Chinese (NCN) patients. Red dots = values observed in Chinese (CN) patients. The dark line is the median, the lower and upper part of the box are 25% and 75% percentile of the distribution, and the lower and upper whiskers are the median–1.5 IQR and median+1.5 IQR. P ‐values calculated from t ‐test. Abbreviations: AE, adverse event; AUC, area under the serum concentration–time curve; AUC1d, AUC from time 0 to the end of dosing interval following the first dose; pCR, pathological complete response; IQR, interquartile range.
非 KM Figure
FIGURE 5FIGURE 5 Relationship between the probability of pCR (A) /having grade ≥3 treatment‐related AEs (B) and AUCdose 1 (AUC1d) or steady state (AUC ss ) for durvalumab. Black solid circles = observed pCR/AE in non‐Chinese (NCN) patients. Red solid circles = the observed pCR/AE in Chinese (CN) patients. Open squares with error bars are the observed probability of response at each exposure quartile. Black lines = the logistic regression between two variables. The grey area represents the associated confidence interval. Abbreviations: AE, adverse event; AUC, area under the serum concentration–time curve; AUC1d, AUC from time 0 to the end of dosing interval following the first dose; AUC ss , AUC at steady state; pCR, pathological complete response.
非 KM Figure